8-K
filed October 9, 2025, 7:59 PM ET
ticker CARM
CIK 0001485003
other material
confidence high
sentiment negative
materiality 1.00
Carisma Therapeutics to be delisted from Nasdaq on Oct 13; expects to wind down operations
Carisma Therapeutics Inc.
- Received Nasdaq delisting letter; common stock suspended from trading effective Oct 13, 2025; no appeal planned.
- Approval received to list common stock on OTCID market tier under symbol CARM starting Oct 13, 2025.
- Company expects to pursue sale or monetization of remaining assets and orderly wind down of operations.
- Warns that it is unlikely there will be meaningful cash available for distribution to stockholders.
- May file Form 15 to suspend SEC reporting obligations after delisting.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001104659-25-098404
- form_type
- 8-K
- ticker
- CARM
- cik
- 0001485003
- company_name
- Carisma Therapeutics Inc.
- filed_at
- 2025-10-09T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:39.506487+00:00
- generated_at
- 2026-05-17T04:10:40.401529+00:00
- sec_items
- ["3.01"]
- event_type
- other_material
- sentiment
- negative
- materiality_score
- 1.0
- calibrated_materiality_score
- 1.0
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001104659-25-098404
- json_url
- https://secwatch.observer/filing/0001104659-25-098404.json
- markdown_url
- https://secwatch.observer/filing/0001104659-25-098404.md
- text_url
- https://secwatch.observer/filing/0001104659-25-098404.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/tm2528458d1_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
XXI
Tether International acquires SoftBank's stake in Twenty One Capital; board members resign
Twenty One Capital, Inc.
May 20, 2026, 8:49 AM ET
other_material
Items 1.02, 3.01, 5.02, 8.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
October 9, 2025, Carisma Therapeutics Inc. (the “Company”)
received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).
The Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing
Rules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.
The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities
and Exchange Commissio
Comparable filing
o independent directors, the minimum number required during the transition period
for compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual
Filing page
SEC filing
SOPA
Society Pass receives Nasdaq delisting notice after filing Chapter 11 bankruptcy
SOCIETY PASS INCORPORATED.
May 20, 2026, 6:05 AM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
October 9, 2025, Carisma Therapeutics Inc. (the “Company”)
received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).
The Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing
Rules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.
The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities
and Exchange Commissio
Comparable filing
May 14, 2026, the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
that Nasdaq had determined to delist the Company’s common stock, par value $0.0001 per share (the
Filing page
SEC filing
BTM
Bitcoin Depot files Chapter 11; Nasdaq to suspend BTM stock and warrants on May 26
Bitcoin Depot Inc.
May 19, 2026, 4:01 PM ET
other_material
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
October 9, 2025, Carisma Therapeutics Inc. (the “Company”)
received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).
The Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing
Rules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.
The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities
and Exchange Commissio
Comparable filing
May 18, 2026, the Company received a letter from the Listing Qualifications Department staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Debtors’ commencement of the Chapter 1
Filing page
SEC filing
RVPH
Reviva Pharmaceuticals to be delisted from Nasdaq May 14, 2026; will trade on OTCQB
REVIVA PHARMACEUTICALS HOLDINGS, INC.
May 13, 2026, 8:03 AM ET
other_material
Items 3.01, 8.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
October 9, 2025, Carisma Therapeutics Inc. (the “Company”)
received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).
The Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing
Rules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.
The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities
and Exchange Commissio
Comparable filing
May 12, 2026 indicating that the Panel had determined to delist the Company’s common stock from Nasdaq. The Company’s common stock will be suspended from trading on Nasdaq as of the open of trading on May 14, 2026. Begin
Filing page
SEC filing
BKYI
BIO-key receives Nasdaq delisting notice; stock to move to OTC Markets on May 13
BIO KEY INTERNATIONAL INC
May 12, 2026, 4:46 PM ET
other_material
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
similar materiality
This filing
October 9, 2025, Carisma Therapeutics Inc. (the “Company”)
received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).
The Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing
Rules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.
The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities
and Exchange Commissio
Comparable filing
May 6, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(a)
Filing page
SEC filing
ADTX
Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11
Aditxt, Inc.
May 29, 2026, 4:21 PM ET
other_material
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
This filing
October 9, 2025, Carisma Therapeutics Inc. (the “Company”)
received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).
The Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing
Rules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.
The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities
and Exchange Commissio
Comparable filing
May 27, 2026, Aditxt, Inc. (the “Company”)
received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market
LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s
Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum
stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)
(the “Stockholders’ Equity Requirement”). The Letter further
Filing page
SEC filing
LIMN
Liminatus Pharma receives Nasdaq delisting notice; appeals filed
Liminatus Pharma, Inc.
May 27, 2026, 4:30 PM ET
other_material
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
This filing
October 9, 2025, Carisma Therapeutics Inc. (the “Company”)
received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).
The Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing
Rules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.
The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities
and Exchange Commissio
Comparable filing
May 20, 2026, the Company received a notice
from Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will
be delisted from The Nasdaq Global Mark
Filing page
SEC filing
EMAT
Evolution Metals regains Nasdaq compliance after late 10-Q filing; notice resolved
Evolution Metals & Technologies Corp.
May 26, 2026, 5:28 PM ET
other_material
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: other_material
This filing
October 9, 2025, Carisma Therapeutics Inc. (the “Company”)
received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).
The Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing
Rules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.
The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities
and Exchange Commissio
Comparable filing
May 21, 2026, Evolution Metals & Technologies
Corp. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The
Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.